Table 3.

Comparison of study data with prevalence in median age group according to current data from Germany

	Our data	Prevalence in median age group
Sex (m:f)	117:142; 55% female	prevalence for PG: 0.3-1.0/100.000
	(Germany: 1000:1040; 51% female)
Age (mean)	21-94 years (57.3 years)
	(Germany, 2010: 44.3 years)
Associated inflammatory disorders
Arthrosis, non rheumatoid arthritis	17 (6.6%)	female (45–65 years): 33%
		male: (45–65 years): 25%
Rheumatoid arthritis	24 (9.3%)	female (45–64 years): 8.6%
		male (45–64 years): 5%
		overall: 0.5-0.8%
Chronic inflammatory bowel disease	Overall: 24 (9.3%)	Crohn’s disease:
	Crohn’s disease:	120-200/100.000
	7 (2.7%)	Ulcerative colitis:
	Ulcerative colitis: 17 (6.6%)	160-250/100.000
Endocrine disorders
Thyroid disease	29 (11.2%)	overall: 5.5%
		female: 8.9%
		male: 1.8%
Diabetes mellitus	66 (25.5%)	international overall (20–79 years): 12%
		German overall: 8.9%
Neoplasia	32 (12.4%)	overall: 5-yr.-prevalence: 1.6%
		10-yr.-prevalence: 2.4%
Solid neoplasms (overall)	22 (8.5%)
Breast cancer	6 (2.3%)	female (50–59 years): 1-year-prevalence: 0.2%
Lung cancer	3 (1.6%)	female: 50–59 years: 1-year-prevalence: 0.04%
		male: 50–59 years: 1-year-prevalence: 0.07%
Prostate cancer	3 (1.6%)	male overall: 1-year-prevalence: 0.1%
		male (60–69 years): 1-year- prevalence: 0.5%
Melanoma	3 (1.6%)	female (50–59 years): 1-year.-prevalence: 0.03%
		male (50–59 years): 1-year life-prevalence: 0.02%
Hepatocellular carcinoma	2 (0.8%)	overall: 7-8/100.000
Ovarian cancer	2 (0.8%)	female (50–59 years): 1-year life-prevalence: 0.03%
Colon cancer	1 (0.4%)	female (50–59 years): 1-year.-prevalence: 0.1%
		male (50–59 years): 1-year-prevalence:
Laryngeal cancer	1 (0.4%)	female: 1-year-prevalence: <0.01%
		male: 1-year-prevalence: <0.1%
Glioblastoma multiforme	1 (0.4%)	n.a.
Hematologic/hematopoetic neoplasia		Leukemia, female:1-year-prevalence: 0.01%
AML	1 (0.4%)
CML	2 (0.8%)	Leukemia, male:
Other	7 (2.8%)	1-year-prevalence: 0.01%